Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
| Website: | www.regulusrx.com |
| Email: | information@regulusrx.com |
| Main Phone: | +1 858 202-6300 |
| Address: | 10628 Science Center Drive |
| Address 2: | Suite 225 |
| State: | CA |
| City / Town: | San Diego |
| Country: | US |
| Postal Code: | 92121 |
| Exchange: | NSC |
| CEO: | Joseph P. Hagan |
| Employees: | 24 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand,
Small-cap companies (that is, companies that are worth between $300 million and $2 billion) can be a risky investment, as smaller companies tend to have lower stock prices and thus are more
Futures Outlook for the Week: 02/4/13This week we are going to cover three C’s: Cocoa, Coffee, and Copper. The first two may be in the market for some counter trend plays and the last of them
LifeLock Inc. (LOCK) began trading as a public company this morning with an initial public offering of 15.7 million shares at $9 each. The $9 per share price tag is below the original price range
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
| Website: | www.regulusrx.com |
| Email: | information@regulusrx.com |
| Main Phone: | +1 858 202-6300 |
| Address: | 10628 Science Center Drive |
| Address 2: | Suite 225 |
| State: | CA |
| City / Town: | San Diego |
| Country: | US |
| Postal Code: | 92121 |
| Exchange: | NSC |
| CEO: | Joseph P. Hagan |
| Employees: | 24 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand,
Small-cap companies (that is, companies that are worth between $300 million and $2 billion) can be a risky investment, as smaller companies tend to have lower stock prices and thus are more
Futures Outlook for the Week: 02/4/13This week we are going to cover three C’s: Cocoa, Coffee, and Copper. The first two may be in the market for some counter trend plays and the last of them
LifeLock Inc. (LOCK) began trading as a public company this morning with an initial public offering of 15.7 million shares at $9 each. The $9 per share price tag is below the original price range
| Last Price 0.55 | Change $ -0.0229 | Change % -3.98 | Tick N/A |
| Bid 0.55 | Bid Size 100.00 | Ask 0.60 | Ask Size 2,000.00 |
| Open 0.59 | High 0.60 | Low 0.55 | Prev Close 0.58 |
| Last Trade | Volume 311,673 | 52 Wk Hi 1.74 | 52 Wk Low 0.43 |
| Market Cap 19.9 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 35,922,916.00 | EPS (TTM) -0.96 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 1 | 10 |
| Number of Buys | 1 | 10 |
| Number of Sells | 0 | 0 |
| Net Activity | 7695 | 2130745 |
| Last 10 Buys | Shares |
|---|---|
| Timothy Michael Wright | 1,000 |
| William H. Rastetter | 1,000 |
| Joseph P. Hagan | 1,000 |
| Stelios Papadopoulos | 1,000 |
| Daniel R. Chevallard | 1,000 |
| Stelios Papadopoulos | 1,000 |
| Stelios Papadopoulos | 1,000 |
| William H. Rastetter | 1,000 |
| Joseph P. Hagan | 1,000 |
| Mark G. Foletta | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Bruce L.A. Carter | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 3 | 3 | 3 | 3 |
| Low Target Price Estimate | 1 | 1 | 1 | 1 |
| Mean Target Price Estimate | 1.77 | 1.77 | 1.77 | 1.77 |
| Standard Deviation | 0.77 | 0.77 | 0.77 | 0.77 |
| Date of Most Recent Estimate | 05/11/18 | 05/11/18 | 05/11/18 | 05/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 3 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2.33 | 2.33 | 2.33 | 2.2 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait